SGLT2 inhibition to address the unmet needs in diabetic nephropathy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2 inhibition to address the unmet needs in diabetic nephropathy
Authors
Keywords
-
Journal
DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume -, Issue -, Pages e3171
Publisher
Wiley
Online
2019-04-18
DOI
10.1002/dmrr.3171
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States
- (2018) Rajiv Saran et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
- (2018) Chiara Ghezzi et al. DIABETOLOGIA
- Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study
- (2018) Giuseppe Penno et al. DIABETOLOGIA
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Sodium–glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice
- (2018) Shinji Tanaka et al. KIDNEY INTERNATIONAL
- Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
- (2018) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
- (2018) Claire C J Dekkers et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection
- (2018) Hiroyuki Umino et al. Scientific Reports
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
- (2018) Eugene Han et al. Frontiers in Endocrinology
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
- (2017) Xiaoxin X. Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits
- (2017) Jens Oellgaard et al. KIDNEY INTERNATIONAL
- Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
- (2017) Adeera Levin et al. LANCET
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis
- (2017) Xiaoling Cai et al. Obesity
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
- (2016) Paola Fioretto et al. DIABETOLOGIA
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
- (2016) Volker Vallon et al. DIABETOLOGIA
- Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
- (2016) Peter Gæde et al. DIABETOLOGIA
- Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
- (2016) Maryam Afkarian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
- (2016) Yanling Zhang et al. PLoS One
- Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
- (2016) Seok Joon Shin et al. PLoS One
- Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
- (2016) Linda A. Gallo et al. Scientific Reports
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding EMPA-REG OUTCOME
- (2015) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
- (2014) Marko Škrtić et al. DIABETOLOGIA
- Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport
- (2014) M. A. Abdul-Ghani et al. JOURNAL OF INTERNAL MEDICINE
- Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
- (2014) H. J. Lambers Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
- (2014) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
- (2014) Muralikrishna Gangadharan Komala et al. PLoS One
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes
- (2013) Kazuhiro Hasegawa et al. NATURE MEDICINE
- The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease
- (2012) Jan Skupien et al. KIDNEY INTERNATIONAL
- Suppression of Oxidative Stress by -Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
- (2012) T. Shimazu et al. SCIENCE
- Early Renal Function Decline in Type 2 Diabetes
- (2011) M. E. Pavkov et al. Clinical Journal of the American Society of Nephrology
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
- Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
- (2011) Hermann Haller et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
- (2010) V. Vallon et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Solute carrier family 2, member 9 and uric acid homeostasis
- (2009) Chris Cheeseman CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes
- (2009) Michael Mauer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now